CoChat
Sign Up
Cited by 456Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and LipoproteinsDiet, Metabolism, and Disease

The DOI matches its Crossref record; 228 of the 231 references it cites were found in a registry or an index.

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options

Open access
Gastaldelli, Amalia, Cusi, Kenneth·2019·JHEP Reports
DOI 10.1016/j.jhepr.2019.07.002PMC PMC7001557
Open this paper in CoChat — free account

Abstract

The worldwide prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to have reached 25% or more in adults. NAFLD is prevalent in obese individuals, but may also affect non-obese insulin-resistant individuals. NAFLD is associated with a 2- to 3-fold increased risk of developing type 2 diabetes (T2D), which may be higher in patients with more severe liver disease - fibrosis increases this risk. In NAFLD, not only the close association with obesity, but also the impairment of many metabolic pathways, including decreased hepatic insulin sensitivity and insulin secretion, increase the risk of developing T2D and related comorbidities. Conversely, patients with diabetes have a higher prevalence of steatohepatitis, liver fibrosis and end-stage liver disease. Genetics and mechanisms involving dysfunctional adipose tissue, lipotoxicity and glucotoxicity appear to play a role. In this review, we discuss the altered pathophysiological mechanisms that underlie the development of T2D in NAFLD and vice versa. Although there is no approved therapy for the treatment of NASH, we discuss pharmacological agents currently available to treat T2D that could potentially be useful for the management of NASH.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhepr.2019.07.002

Cites

228 of 228 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Natural history of T2D in the context of NAFLD. T2D results from an imbalance between insulin sensitivity and insulin secretion. In the progression from normal to impaired glucose tolerance to T2D, insulin secretion increases to overcome insulin resistance. At the same time there is a decrease in insulin clearance (mainly hepatic), especially in individuals with NAFLD, that determines higher peripheral insulin concentrations. However, despite high concentrations, insulin secreted is insufficient (beta-cell dysfunction) and therefore there is an increase in both fasting and postprandial glucose concentrations. Subjects become T2D only when the beta cells are unable to increase insulin secretion (beta-cell failure) and overcome peripheral IR. Redrawn from ref 8,11,13. IR, insulin resistance; NAFLD, non-alcoholic fatty liver disease; NGT, normal glucose tolerance; T2D, type 2 diabetes
Fig. 1 Natural history of T2D in the context of NAFLD. T2D results from an imbalance between insulin sensitivity and insulin secretion. In the progression from normal to impaired glucose tolerance to T2D, insulin secretion increases to overcome insulin resistance. At the same time there is a decrease in insulin clearance (mainly hepatic), especially in individuals with NAFLD, that determines higher peripheral insulin concentrations. However, despite high concentrations, insulin secreted is insufficient (beta-cell dysfunction) and therefore there is an increase in both fasting and postprandial glucose concentrations. Subjects become T2D only when the beta cells are unable to increase insulin secretion (beta-cell failure) and overcome peripheral IR. Redrawn from ref 8,11,13. IR, insulin resistance; NAFLD, non-alcoholic fatty liver disease; NGT, normal glucose tolerance; T2D, type 2 diabetesCC BY-NC-ND · PubMed Central
Fig. 2 Insulin resistance causes excess substrate (amino acids, glycerol, FFAs) to be transported to the liver. Excess substrate (amino acids, glycerol, FFAs) stimulate GNG, glucose fluxes, de novo glycerol synthesis, TG synthesis and DNL. Moreover, the synthesis of lipotoxic compounds like DAGs and ceramides is enhanced. Modified from 32. DAGs, diacylglycerols; DNL, de novo lipogenesis; FFAs, free fatty acids; GNG, gluconeogenesis; TG, triglyceride; VLDL, very low-density lipoprotein.
Fig. 2 Insulin resistance causes excess substrate (amino acids, glycerol, FFAs) to be transported to the liver. Excess substrate (amino acids, glycerol, FFAs) stimulate GNG, glucose fluxes, de novo glycerol synthesis, TG synthesis and DNL. Moreover, the synthesis of lipotoxic compounds like DAGs and ceramides is enhanced. Modified from 32. DAGs, diacylglycerols; DNL, de novo lipogenesis; FFAs, free fatty acids; GNG, gluconeogenesis; TG, triglyceride; VLDL, very low-density lipoprotein.CC BY-NC-ND · PubMed Central
Fig. 3 Relationship between adipose tissue insulin resistance and dysfunction and insulin resistance in liver and muscle. Dysfunctional adipose tissue displays resistance to the antilipolytic effect of insulin with increased lipolysis and release of FFAs and glycerol that in turn are responsible for triglyceride accumulation and lipotoxicity in the liver, muscle and pancreas, impairing insulin secretion. Moreover, dysfunctional adipose tissue releases adipokines that activate pro-inflammatory pathways in these organs. FFAs, free fatty acids.
Fig. 3 Relationship between adipose tissue insulin resistance and dysfunction and insulin resistance in liver and muscle. Dysfunctional adipose tissue displays resistance to the antilipolytic effect of insulin with increased lipolysis and release of FFAs and glycerol that in turn are responsible for triglyceride accumulation and lipotoxicity in the liver, muscle and pancreas, impairing insulin secretion. Moreover, dysfunctional adipose tissue releases adipokines that activate pro-inflammatory pathways in these organs. FFAs, free fatty acids.CC BY-NC-ND · PubMed Central
Fig. 4 Relationship between lipo- and glucotoxicity, insulin resistance and beta-cell function. Both lipotoxicity and glucotoxicity contribute to insulin resistance, ectopic fat accumulation and beta-cell dysfunction and vice versa. In NAFLD, lipotoxicity and insulin resistance have been recognised as pathophysiological mechanisms responsible of development and progression to a more severe form of this disease. T2D is a chronic condition of glucotoxicity, although also lipotoxicity is often present and are responsible not only of insulin resistance but also of impaired insulin secretion. DAG, diacylglycerol; DNL, de novo lipogenesis; NAFLD, non-alcoholic fatty liver disease; ROS, reactive oxygen species; T2D, type 2 diabetes.
Fig. 4 Relationship between lipo- and glucotoxicity, insulin resistance and beta-cell function. Both lipotoxicity and glucotoxicity contribute to insulin resistance, ectopic fat accumulation and beta-cell dysfunction and vice versa. In NAFLD, lipotoxicity and insulin resistance have been recognised as pathophysiological mechanisms responsible of development and progression to a more severe form of this disease. T2D is a chronic condition of glucotoxicity, although also lipotoxicity is often present and are responsible not only of insulin resistance but also of impaired insulin secretion. DAG, diacylglycerol; DNL, de novo lipogenesis; NAFLD, non-alcoholic fatty liver disease; ROS, reactive oxygen species; T2D, type 2 diabetes.CC BY-NC-ND · PubMed Central
Fig. 5 Effect of SGLT2 inhibitor on IHTG and body weight. Left panel: Effect of the SGLT2 inhibitor canagliflozin vs. placebo on relative IHTG content among all patients (left) or only patients with a diagnosis of NAFLD (right) at baseline. Right panel: Relationship between changes in body weight after canagliflozin or placebo treatment and change in IHTG. Reproduced with permission from 218. IHTG, intrahepatic triglyceride; NAFLD, non-alcoholic fatty liver disease.
Fig. 5 Effect of SGLT2 inhibitor on IHTG and body weight. Left panel: Effect of the SGLT2 inhibitor canagliflozin vs. placebo on relative IHTG content among all patients (left) or only patients with a diagnosis of NAFLD (right) at baseline. Right panel: Relationship between changes in body weight after canagliflozin or placebo treatment and change in IHTG. Reproduced with permission from 218. IHTG, intrahepatic triglyceride; NAFLD, non-alcoholic fatty liver disease.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 231 references

Research works printed but not linked: 1

  1. Gastaldelli, 2014, Chapter 3: Pathophysiology of Prediabetes: Role of Lipotoxicity?, Volume 1, 31

Cited by

Sorted by citations

Items 101–200 of 456

Related

See all

Metadata

Authors
Gastaldelli, A., & Cusi, K.
Affiliations
  • Istituto di Fisiologia Clinica (IT)
  • University of Florida (US)
Corresponding author
  • Gastaldelli, Amalia
  • Cusi, Kenneth
ORCID
Venue
JHEP Reports
Publisher
Elsevier BV
Published
2019-10
Volume
1
Issue
4
Pages
312-328
ISSN
2589-5559 (ISSN-L)
DOI
10.1016/j.jhepr.2019.07.002
PMC
PMC7001557
OpenAlex
W2963543751
Cited by
455
References
231
Citations by year
2026: 48 · 2025: 69 · 2024: 85 · 2023: 74 · 2022: 62 · 2021: 78 · 2020: 34 · 2019: 3
FWCI
6.46
Type
journal article
Language
en
Open access
Licence
Locations
  • JHEP Reports (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Horizon H2020 (634413)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
Keywords
non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, insulin resistance, hepatic insulin sensitivity, insulin secretion, liver fibrosis, end-stage liver disease, lipotoxicity, glucotoxicity, adipose tissue dysfunction, obesity, antidiabetic drugs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review